Carlyle's IPO Playbook: Navigating Volatility with High-Value Exits and Service Sector Strength

As global markets grapple with fluctuating interest rates and geopolitical tensions, private equity firms are under pressure to demonstrate resilience and adaptability. Among them, The Carlyle Group (CAR) has positioned itself as a strategic outlier, leveraging its portfolio of high-margin service-based industries and selective leveraged buyout (LBO) opportunities to navigate volatility. With a stated $5 billion IPO exit target for 2025 and a $50 billion+ valuation play for its flagship asset, Medline Industries, Carlyle's strategy underscores a clear path to capitalize on market recovery—and investors should take note.

The IPO Pipeline: Medline's $50 Billion Ambition

At the heart of Carlyle's exit strategy is Medline Industries, a $34 billion club deal acquired in 2021 alongside Blackstone and Hellman & Friedman. The company, which dominates the global medical supplies market, is now preparing for an IPO that could value it at over $50 billion.

. With $23 billion in 2023 revenue and a network spanning 100+ countries, Medline's scale and diversification—ranging from surgical equipment to lab devices—position it as a bellwether for Carlyle's exit ambitions.

The IPO's success hinges on its timing. Carlyle is banking on a rebound in IPO markets, fueled by stabilizing inflation and record-high stock valuations. While geopolitical risks linger, Medline's insulation from tariffs—due to its service-based business model and U.S.-centric supply chain—reduces exposure to trade headwinds. This strategic advantage is mirrored across 80% of Carlyle's portfolio, which focuses on industries such as healthcare, logistics, and technology, all of which are less prone to trade disruptions.

Fund Performance: Growth Amid Near-Term Pressures

Carlyle's confidence in its exit strategy is bolstered by strong fund performance. Despite a modest dip in Q4 2024 distributable earnings (to $209.6 million from $276.1 million in 2023), its U.S. buyout funds delivered 15% and 21% growth in 2024. These figures signal underlying strength, even as the firm anticipates modest declines in private equity fees in 2025. The resilience of its portfolio suggests Carlyle can weather short-term market volatility while capitalizing on long-term opportunities.

.

Club Deals: A Return to Strategic Collaborations

Carlyle's Medline partnership exemplifies its renewed focus on “club deals”—large-scale joint ventures with other private equity giants. Such deals, which fell out of favor post-2008 financial crisis, now re-emerge as a tool to acquire dominant market players like Medline. By sharing risk and expertise, Carlyle reduces exposure to single-asset downturns while amplifying returns. This strategy aligns with its focus on industry leaders, a move that could prove critical as markets consolidate.

LBOs and the M&A Recovery Play

While Carlyle scales back on aggressive LBOs amid higher interest rates, it remains selective in targeting high-margin sectors. The firm's Q4 2024 earnings call emphasized its preference for companies with “pricing power and recurring revenue streams,” such as StandardAero (which saw a 19% post-IPO surge in October 2024). These attributes are increasingly rare in a volatile economy, making Carlyle's portfolio a rare haven for investors seeking stability.

Investment Thesis: Positioning for Second-Half Recovery

Carlyle's dual focus on IPO exits and service-sector resilience offers a compelling case for investors. Key takeaways:
1. Medline's IPO: A $50 billion valuation could unlock substantial returns for Carlyle's investors, particularly if the IPO proceeds align with broader market optimism. Historical backtests show that while earnings beats have boosted CAR's stock price on announcement days, subsequent 60-day holding periods have seen limited gains amid elevated volatility, underscoring the need for disciplined timing.
2. Portfolio Resilience: The 80% service-sector concentration acts as a natural hedge against tariff and geopolitical risks—a rarity in today's markets. This diversification, paired with a track record of outperforming near-term headwinds, reinforces CAR's long-term appeal.
3. Club Deals as Catalysts: Collaborations like Medline demonstrate Carlyle's ability to access high-value assets while mitigating risk—a model that could attract institutional capital.

While Carlyle's stock price has lagged peers in the near term (), its long-term strategy is well-calibrated for a second-half M&A rebound. As interest rate cuts revive dealmaking and public markets reopen, Carlyle's pipeline of IPO-ready assets positions it to lead the recovery.

Conclusion: A Play for Patient, Strategic Investors

Carlyle's $5 billion exit target is more than a financial goal—it's a bet on the durability of service-based industries and the power of strategic partnerships. Investors seeking exposure to healthcare, logistics, and technology through a private equity lens would do well to monitor Carlyle's progress. With Medline's IPO on the horizon and fund performance defying near-term headwinds, the firm's playbook offers a roadmap for navigating volatility—and profiting from it.

Final recommendation: Consider a gradual build in exposure to Carlyle Group (CAR) as IPO markets stabilize, with a focus on its Q4 2025 results and Medline's valuation realization. However, historical backtests from 2020–2025 highlight the importance of risk management: while earnings beats can trigger short-term gains, the subsequent 60-day period has seen limited returns and significant volatility, necessitating a focus on timely exits.